Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GlaxoSmithKline ( (GB:GSK) ) has provided an update.
GSK has secured European Commission approval for a new prefilled syringe presentation of its shingles vaccine Shingrix, which is already authorised in the EU for prevention of herpes zoster and post-herpetic neuralgia in adults at risk, marking an incremental innovation in its established vaccines franchise. The prefilled format, which will roll out across EU countries from 2026, is designed to simplify administration for healthcare professionals by eliminating the current two‑vial reconstitution process, potentially supporting broader and more efficient vaccination against a disease that affects around 1.7 million people annually in Europe and poses heightened risks for older adults and those with chronic conditions such as cardiovascular disease, diabetes and chronic kidney disease.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.60 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company that focuses on uniting science, technology and talent to develop vaccines and medicines aimed at getting ahead of disease, with a portfolio that includes Shingrix, its recombinant zoster vaccine for preventing shingles and related complications in adults.
Average Trading Volume: 8,205,920
Technical Sentiment Signal: Buy
Current Market Cap: £73.44B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.